Broadly, the purpose of this project is to evaluate the baseline stroke and dementia risk of those Indvidual identified by NLP and characterize the population identified during the recruitment process through enrollment. Additionally, we seek to assess changes to medical care and medications in the 90-days after being informed of the NLP findings.
The goal of this protocol is to validate a non-contact technology with miniaturized radar integrated with a visible camera in a high-risk neonatal population to ultimately provide a safe alternative to current standard contact vital sign monitoring systems.
we plan to use non invasive ADP (air displacement plethysmography) method to measure body composition in very low birth weight infants and follow their neurodevelopment using HINE (Hammersmith Infant Neurological examination)
Aortic stenosis (AS) affects over 12.6 million adults and causes an estimated 102,700 deaths annually. There is interest in novel approaches to identify valve disease earlier the disease course before symptoms occur. We previously used machine learning (ML) to develop a system for fully automated AS screening. Here we are validating the performance of this new method for identifying AS.
This will be a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PLS240 in eligible participants with ESKD and SHPT.
This study aims to learn more about the investigational drug, ASTX727, and another drug, venetoclax, when given in combination. It also aims to evaluate potential pharmocokinetics (PK) interactions for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy.
